Daiichi takes 130 reps off Merck KgAA's hands

More evidence that pharma sales is fraught with change: Daiichi Sankyo's German unit has agreed to take over most of Merck KGaA's primary care sales operation, which amounts to about 130 workers. Report

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?